Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy.
The pathogenesis and therapy of shrinking lungs syndrome in patients with systemic lupus erythematosus remains controversial. It has been previously reported that corticosteroid treatment can be effective. We report a patient with shrinking lungs syndrome who presented a good response to inhaled beta-agonist therapy. Therapeutic approach to this syndrome is discussed.
Muñoz-Rodríguez
F J
FJ
Systemic Autoimmune Diseases Unit, Hospital Clínic i Provincial, Barcelona, Catalonia, Spain.
Font
J
J
Badia
J R
JR
Miret
C
C
Barberà
J A
JA
Cervera
R
R
Ingelmo
M
M
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000503:physiopathology; D012123:Pulmonary Ventilation; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000420:Albuterol